INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7501, 0, 'Indapamide', 'Hyperuricemia', 'Thiazide diuretics decrease the rate of uric acid excretion.  Hyperuricemia occurs frequently but is usually asymptomatic and rarely leads to clinical gout except in patients with a history of gout or chronic renal failure.  Therapy with thiazide diuretics should be administered cautiously in such patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7502, 0, 'Indapamide', 'Thyroid Diseases', 'Thiazide diuretics may decrease serum PBI (protein-bound iodine) levels without associated thyroid disturbance.  Clinicians should be cognizant of this effect when prescribing or administering thiazide therapy to patients with thyroid disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7503, 0, 'Indomethacin', 'Asthma', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated in patients with history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients.  A subpopulation of patients with asthma may have aspirin-sensitive asthma which may include chronic rhinosinusitis complicated by nasal polyps, severe potentially fatal bronchospasm, and/or intolerance to aspirin and other NSAIDs.  Since cross-reactivity between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, therapy with any NSAID should be avoided in patients with this form of aspirin sensitivity.  NSAIDs should be used with caution in patients with preexisting asthma (without known aspirin sensitivity), and these patients should be monitored for changes in the signs and symptoms of asthma.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7504, 0, 'Indomethacin', 'Water-Electrolyte Imbalance', 'Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs).  Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure.  Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7505, 0, 'Indomethacin', 'Peptic Ulcer', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal.  These serious adverse events can develop at any time, with or without warning symptoms.  Only 1 in 5 patients who develop a serious upper GI side effect on NSAIDs is symptomatic.  NSAIDs should be used with caution in patients with history of peptic ulcer disease and/or GI bleeding, as these patients had a greater than 10-fold increased risk for developing a GI bleed compared to patients without these risk factors.  Caution is also advised if NSAIDs are prescribed to patients with other factors that increase risk of GI bleeding, such as:  prolonged NSAID therapy; concomitant use of oral corticosteroids, antiplatelet agents (e.g., aspirin), anticoagulants, selective serotonin reuptake inhibitors; alcohol use; smoking; history of gastrointestinal surgery or anastomosis, older age; poor general health status; and advanced liver disease and/or coagulopathy.  Particular vigilance is necessary when treating elderly or debilitated patients since most postmarketing reports of fatal GI events occurred in these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7506, 0, 'Indomethacin', 'Exanthema', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause serious skin adverse reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, and exfoliative dermatitis), which can be fatal.  These serious events may occur without warning.  Patients should be advised to discontinue the NSAID and seek medical attention promptly at the first sign of skin rash or any other sign of hypersensitivity.  NSAIDs are contraindicated in patients with previous serious skin reactions to these drugs.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7507, 0, 'Indomethacin', 'Kidney Diseases', 'Long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) has resulted in renal papillary necrosis and other renal injury.  Renal toxicity has been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion:  in such patients, NSAIDs may cause a dose-dependent reduction in prostaglandin synthesis and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.  Patients at greatest risk for this reaction include the elderly, those with impaired renal function, dehydration, hypovolemia, heart failure, or liver dysfunction, and those taking diuretics, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers; discontinuation of NSAID therapy will usually lead to recovery to the pretreatment state.  No information is available regarding use NSAIDs in patients with advanced renal disease; the renal effects of NSAIDs may hasten the progression of renal dysfunction in patients with preexisting renal disease.  Volume status should be corrected in dehydrated or hypovolemic patients prior to initiating treatment.  Renal function should be monitored during therapy in patients with renal or liver dysfunction, heart failure, dehydration, or hypovolemia.  NSAIDs should be avoided in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function; if an NSAID is used in such patients, they should be monitored for signs of worsening renal function.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7508, 0, 'Indomethacin', 'Thrombosis', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.  This risk may occur early in treatment and may increase with duration of use.  Clinical trials of several cyclooxygenase-2 (COX-2) selective and nonselective NSAIDs of up to 3 years duration have supported this increased risk.  It is unclear from available data if the risk for cardiovascular thrombotic events is similar for all NSAIDs.  Therapy with NSAIDs should be administered cautiously in patients with a history of cardiovascular or cerebrovascular disease.  Patients should be treated with the lowest effective dosage for the shortest duration necessary.  Appropriate antiplatelet therapy should be administered to patients requiring cardioprotection; however, there is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious cardiovascular thrombotic events associated with NSAID use, while the risk of serious gastrointestinal events is increased.  Physicians and patients should remain alert for the development of adverse cardiovascular events throughout the entire duration of therapy, even without prior cardiovascular symptoms.  Patients should be advised to promptly seek medical attention if they experience symptoms of cardiovascular thrombotic events (including chest pain, shortness of breath, weakness, or slurring of speech).NSAIDs are contraindicated in the setting of coronary artery bypass graft (CABG) surgery.  Two large clinical trials of a COX-2 selective NSAID for the treatment of pain in the first 10 to 14 days following CABG surgery found an increased incidence of myocardial infarction and stroke.The use of NSAIDs should be avoided in patients with a recent myocardial infarction unless the benefits are expected to outweigh the risk of recurrent cardiovascular thrombotic events.  If an NSAID is used in patients with a recent myocardial infarction, they should be monitored for signs of cardiac ischemia.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7509, 0, 'Indomethacin', 'Central Nervous System Diseases', 'The use of indomethacin has been reported to aggravate depression or other psychiatric disturbances, epilepsy, and parkinsonism.  Therapy with indomethacin should be administered cautiously in patients with a history of these conditions.  If severe CNS adverse reactions develop, indomethacin should be withdrawn.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7510, 0, 'Indomethacin', 'Anemia', 'Anemia has been reported in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  This may be due to fluid retention, occult/gross blood loss, or an incompletely described effect on erythropoiesis.  Hemoglobin or hematocrit should be monitored in patients with any signs/symptoms of anemia or blood loss, especially during long-term therapy.  NSAIDs may increase risk of bleeding events; comorbid conditions (e.g., coagulation disorders; concomitant use of warfarin/other anticoagulants, antiplatelet agents, serotonin/serotonin norepinephrine reuptake inhibitors) may increase this risk, and patients with these conditions should be monitored for signs of bleeding.  Therapy with NSAIDs should be administered cautiously in patients with or predisposed to anemia.  Clinical monitoring of hematopoietic function may be appropriate, particularly during chronic therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7511, 0, 'Indomethacin', 'Heart Failure', 'Fluid retention and edema have been observed in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs), including some topical formulations.  These drugs should be avoided in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure.  If an NSAID is used in patients with severe heart failure, they should be monitored for signs of worsening heart failure.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7512, 0, 'Indomethacin', 'Liver Diseases', 'Borderline elevations of 1 or more liver tests may occur in up to 15% of patients treated with nonsteroidal anti-inflammatory drugs (NSAIDs).  These laboratory abnormalities may progress, remain unchanged, or regress with continuing therapy.  Elevations of ALT or AST (at least 3 times the upper limit of normal) have been reported in about 1% of patients in clinical trials.  In addition, rare (sometimes fatal) cases of severe hepatotoxicity, including liver necrosis, hepatic failure, jaundice, and fulminant hepatitis have been reported.  Therapy with NSAIDs should be administered cautiously in patients with preexisting liver disease.  Periodic monitoring of liver function is recommended during prolonged therapy.  NSAIDs are also highly protein-bound and some are extensively metabolized by the liver.  Metabolic activity and/or plasma protein binding may be altered in patients with hepatic impairment.  A dosage reduction may be required in some cases.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7513, 0, 'Indomethacin', 'Hyperkalemia', 'Increases in serum potassium concentration (including hyperkalemia) have been reported with use of nonsteroidal anti-inflammatory drugs (NSAIDs), even in some patients without renal impairment.  In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.  Caution is advised in patients with hyperkalemia.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7514, 0, 'Indomethacin', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7515, 0, 'Indomethacin', 'Blood Platelet Disorders', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) reversibly inhibit platelet adhesion and aggregation and may prolong bleeding time in some patients.  With the exception of aspirin, the platelet effects seen with most NSAIDs at usual recommended dosages are generally slight and of relatively short duration but may be more pronounced in patients with underlying hemostatic abnormalities.  Thrombocytopenia has also been reported rarely during NSAID use.  Therapy with NSAIDs should be administered cautiously in patients with significant active bleeding or a hemorrhagic diathesis, including hemostatic and/or coagulation defects associated with hemophilia, vitamin K deficiency, hypoprothrombinemia, thrombocytopenia, thrombocytopathy, or severe hepatic impairment.  NSAIDs that selectively inhibit cyclooxygenase-2 (i.e., COX-2 inhibitors) do not appear to affect platelet function or bleeding time at indicated dosages and may be preferable if risk of bleeding is a concern.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7516, 0, 'Imiquimod (topical)', 'Eczema', 'Imiquimod may exacerbate inflammatory conditions of the skin.  Local reactions are commonly associated with the use of imiquimod and may extend beyond the application site onto the surrounding skin.  These reactions include erythema, edema, vesicles, erosion/ulceration, weeping/exudate, flaking/scaling/dryness, and scabbing/crusting.  Therapy with topical imiquimod should be avoided or used with caution in patients with eczematous conditions.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7517, 0, 'Imiquimod (topical)', 'Sunburn', 'The use of imiquimod may be associated with heightened sunburn susceptibility.  Patients with sunburn should be cautioned not to use imiquimod until fully recovered.  Exposure to sunlight, including sunlamps, should be avoided or minimized during treatment, and protective clothing (e.g., hat) is recommended when exposure is unavoidable.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7518, 0, 'Imatinib', 'Cardiovascular Diseases', 'Cardiovascular events, including arterial vascular occlusive events, peripheral arterial occlusive events and ischemic cerebrovascular events have been reported in patients receiving tyrosine kinase inhibitors.  If acute signs or symptoms of cardiovascular events occur, patients should seek immediate medical attention.  The cardiovascular status and risk factors of patients should be evaluated prior to therapy and cardiovascular monitoring and management should take place during treatment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7519, 0, 'Imatinib', 'Water-Electrolyte Imbalance', 'Fluid retention occurs with BCR-ABL tyrosine kinase inhibitors therapy and may manifest as pericardial effusion, pleural effusion, pulmonary edema, and/or peripheral edema.  Caution should be taken when using these drugs in patients with preexisting fluid retention or congestive heart failure.  Monitor and manage patients using standards of care.  Interrupt, reduce dose or discontinue therapy as necessary.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7520, 0, 'Imatinib', 'Bone Marrow Failure Disorders', 'Thrombocytopenia, aplastic anemia, agranulocytosis and neutropenia occur with BCR-ABL tyrosine kinase inhibitors.  Therapy with these drugs should be administered cautiously in patients with preexisting bone marrow suppression.  A complete blood count should be performed every 1-2 weeks for the first month of therapy and then monthly thereafter, or as clinically indicated.  To manage myelosuppression, withhold, reduce dose, or discontinue therapy as necessary.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7521, 0, 'Imatinib', 'Gastrointestinal Diseases', 'Imatinib has been sometimes associated with GI irritation, and it should be taken with food and a large glass of water to minimize this problem.  There have been rare reports, including fatalities, of gastrointestinal perforation.  Caution should be used in patients with history of GI disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7522, 0, 'Imatinib', 'Hepatic Insufficiency', 'Patients with severe hepatic impairment tend to have higher exposure to both imatinib and its metabolite than patients with normal hepatic function, and dose might need to be adjusted accordingly.  Additionally, there have been reports of hepatotoxicity both with short and long term use of imatinib.  Liver function should be monitored before initiation of treatment and regularly during therapy.  Dose reduction or interruption might be needed if laboratory abnormalities are found.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7523, 0, 'Imatinib', 'Hypothyroidism', 'Hypothyroidism cases have been reported in thyroidectomy patients undergoing levothyroxine replacement therapy during treatment with imatinib.  Caution should be used in these patients and TSH levels should be monitored closely.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7524, 0, 'Imatinib', 'Kidney Diseases', 'The mean exposure to imatinib is increased in patients with renal impairment compared to those with normal renal function.  Dose reductions are necessary in patients with moderate and severe renal impairment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7525, 0, 'Inebilizumab', 'Hepatitis B', 'The use of inebilizumab is contraindicated in patients with active hepatitis B infection.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7526, 0, 'Inebilizumab', 'Tuberculosis', 'The use of inebilizumab is contraindicated in patients with active or untreated latent tuberculosis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7527, 0, 'Inebilizumab', 'Infections', 'An increased risk of infections has been observed with the use of inebilizumab.  It is recommended to delay administration in patients with an active infection until the infection is resolved.  Perform HBV screening in all patients before initiation of treatment.  Do not administer this agent to patients with active hepatitis.  Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating treatment.  Consider anti-tuberculosis therapy in patients with a history of latent active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection.  Consult infectious disease experts regarding whether initiating therapy is appropriate before starting treatment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7528, 0, 'Imipramine', 'Anticholinergic Syndrome', 'Tricyclic and tetracyclic antidepressants (TCAs) have anticholinergic activity, to which elderly patients are particularly sensitive.  Tertiary amines such as amitriptyline and trimipramine tend to exhibit greater anticholinergic effects than other agents in the class.  Therapy with TCAs should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  In patients with angle-closure glaucoma, even average doses can precipitate an attack.  Glaucoma should be treated and under control prior to initiation of therapy with TCAs, and intraocular pressure monitored during therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7529, 0, 'Imipramine', 'Cardiovascular Diseases', 'Tricyclic and tetracyclic antidepressants (TCAs) may cause orthostatic hypotension, reflex tachycardia, syncope, and dizziness, particularly during initiation of therapy or rapid escalation of dosage.  Imipramine appears to have the greatest propensity to induce these effects, while secondary amines such as nortriptyline may do so less frequently.  Tolerance to the hypotensive effects often develops after a few doses to a few weeks.  Rarely, collapse and sudden death have occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include tachycardia, arrhythmias, heart block, hypertension, thrombosis, thrombophlebitis, myocardial infarction, strokes, congestive heart failure, and ECG abnormalities such as PR and QT interval prolongation.  Therapy with TCAs should be avoided during the acute recovery phase following myocardial infarction, and should be administered only with extreme caution in patients with hyperthyroidism, a history of cardiovascular or cerebrovascular disease, or a predisposition to hypotension.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  Many of the newer antidepressants, including bupropion and the selective serotonin reuptake inhibitors (SSRIs), are considerably less or minimally cardiotoxic and may be appropriate alternatives.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7530, 0, 'Imipramine', 'Pheochromocytoma', 'Tricyclic and tetracyclic antidepressants (TCAs) may potentiate the effects of circulating catecholamines.  Enhanced sympathetic activity can provoke hypertensive crises in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas.  Therapy with TCAs should be administered cautiously in patients with these tumors.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7531, 0, 'Imipramine', 'Acute Myocardial Infarction Recovery', 'The use of most tricyclic antidepressants is contraindicated in patients that are going through the acute recovery period after a myocardial infarction.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7532, 0, 'Imipramine', 'Depressive Disorder', 'Adult and pediatric patients with depression may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7533, 0, 'Imipramine', 'Epilepsy', 'Tricyclic antidepressants (TCAs), can lower the seizure threshold and trigger seizures.  These drugs should be used with extreme caution in patients with a history of seizures, or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.  Daily dose restrictions might apply for specific antidepressants.  Physicians are encouraged to get additional dosing recommendations on the manufacturer''s prescribing information.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7534, 0, 'Imipramine', 'Bone Marrow Failure Disorders', 'The use of tricyclic and tetracyclic antidepressants (TCAs) has rarely been associated with bone marrow suppression.  Leukopenia, agranulocytosis, thrombocytopenia, anemia, eosinophilia, purpura, and pancytopenia have been reported with some TCAs.  Patients with preexisting bone marrow suppression or blood dyscrasias receiving TCAs should be monitored closely during therapy for further decreases in blood counts.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7535, 0, 'Imipramine', 'Diabetes Mellitus', 'Both elevation and lowering of blood sugar levels have been reported with the use of some tricyclic antidepressants (TCAs).  Rarely, these effects have also occurred with maprotiline, a tetracyclic antidepressant.  Patients with diabetes should be monitored for worsening control of blood glucose when treated with these agents, particularly during dosage escalation or whenever dosage has been altered.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7536, 0, 'Imipramine', 'Liver Diseases', 'Tricyclic and tetracyclic antidepressants (TCAs) are known to undergo metabolism in the liver.  Some of the metabolites, such as those of imipramine, clomipramine and desipramine, may be pharmacologically active.  Many of the metabolites are also excreted by the kidney.  There are very limited data concerning the use of TCAs in patients with renal and/or liver disease.  Therapy with TCAs should be administered cautiously in patients with significantly impaired renal or hepatic function.  Dosage adjustments may be necessary.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7537, 0, 'Imipramine', 'Schizophrenia', 'Tricyclic antidepressants (TCAs) may aggravate symptoms of psychosis in schizophrenic patients, particularly those with paranoid symptomatology.  Depressed patients, usually those with bipolar disorder, may experience a switch from depression to mania or hypomania.  These occurrences have also been reported rarely with the tetracyclic antidepressant, maprotiline.  Therapy with these agents should be administered cautiously in patients with schizophrenia, bipolar disorder, or a history of mania.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7538, 0, 'Imipramine', 'Tardive Dyskinesia', 'Tricyclic and tetracyclic antidepressants (TCAs) have anticholinergic activity, to which elderly patients are particularly sensitive.  Tertiary amines such as amitriptyline and trimipramine tend to exhibit greater anticholinergic effects than other agents in the class.  As with other drugs that possess anticholinergic activity, TCAs may aggravate tardive dyskinesia or induce previously suppressed symptoms.  Patients with tardive dyskinesia requiring therapy with TCAs should be monitored for exacerbation of the condition.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7539, 0, 'Imipramine', 'Alcoholic Intoxication', 'Tricyclic antidepressants can enhance the response to alcohol.  In patients who may use alcohol excessively, it should be borne in mind that the potentiation may increase the danger inherent in any suicide attempt or overdosage.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7540, 0, 'Imipramine', 'Bipolar Disorder', 'A major depressive episode can be the initial presentation of bipolar disorder.  Patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder prior to initiating treatment with a tricyclic antidepressant.  This screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.  It should be noted that tricyclic antidepressants are not approved for use in treating bipolar depression.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7541, 0, 'Imipramine', 'Glaucoma', 'Tricyclic antidepressants as other type of antidepressants have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with anatomically narrow angle or history of glaucoma.  Doxepin hydrochloride capsules are contraindicated in patients with glaucoma.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7542, 0, 'Imipramine', 'Neutropenia', 'The use of some tricyclic antidepressants has been associated with neutropenia (ANC < 500/mm3) and agranulocytosis (ANC < 500/mm3).  Leukocyte and differential blood counts should be performed in patients that develop fever and sore throat during treatment.  Therapy should be discontinued if there is evidence of pathologic neutrophil depression.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7543, 0, 'Imipramine', 'Thyroid Diseases', 'Most tricyclic antidepressants should be administered with caution in hyperthyroid patients or those receiving thyroid medication as they may develop arrhythmias when these drugs are given.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7544, 0, 'Imipramine', 'Urinary Retention', 'Due to their anticholinergic properties, tricyclic antidepressants should be administered with caution in patients with history of urinary retention.  Particularly doxepin hydrochloride capsules are contraindicated in patients with tendency to urinary retention.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7545, 0, 'Insulin detemir', 'Liver Diseases', 'Insulin requirements may be diminished in patients with renal or hepatic impairment due to reduced insulin metabolism and, in the latter case, also to reduced capacity for gluconeogenesis.  Lower initial dosages may be appropriate, with careful monitoring of plasma glucose levels and dosing adjustments.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7546, 0, 'Insulin detemir', 'Hypokalemia', 'Hypokalemia may commonly occur during treatment with insulin.  Use with caution in patients who may be particularly at risk of developing hypokalemia (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7547, 0, 'Insulin detemir', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7548, 0, 'Infliximab', 'Heart Failure', 'In a study of patients with moderate to severe heart failure (New York Heart Association [NYHA] Functional Class III/IV), an increase incidence of death and hospitalization due to worsening of heart failure was observed after treatment with infliximab at 10 mg/kg.  Infliximab at doses > 5 mg/kg is contraindicated in patients with moderate to severe heart failure.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7549, 0, 'Infliximab', 'Liver Diseases', 'Severe hepatic reactions, including acute liver failure, jaundice, hepatitis and cholestasis, have been reported with the use of infliximab.  Infliximab should be discontinued if jaundice and/or marked liver enzyme elevations (e.g., greater than or equal to 5 times the upper limit of normal) develop and a thorough investigation of the abnormality should be undertaken.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7550, 0, 'Infliximab', 'Infections', 'There have been reports of serious infections, including sepsis and opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis and tuberculosis with TNF blockers.  Treatment with these agents should not be initiated in patients with an active infection, including clinically important localized infections.  Caution and close monitoring is recommended when considering their use in patients with a history of recurrent infections, underlying conditions which may predispose them to infections, or chronic, latent, or localized infections.  Administration of these agents should be discontinued if a patient develops a serious infection or sepsis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7551, 0, 'Infliximab', 'Neoplasms', 'In clinical trials malignancies have been observed in patients receiving TNF-blockers agents.  Patients with psoriasis should be monitored for non-melanoma skin cancers (NMSCs), particularly those patients who have had prior prolonged phototherapy treatment.  Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF blocker therapy.  Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.  Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF blockers.  Caution should be exercised when considering these agents in the treatment of patients with a history of malignancies or in continuing treatment in patients who develop malignancies while receiving these agents.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7552, 0, 'Infliximab', 'Neurotoxicity Syndromes', 'The use of TNF blocking agents has been associated with rare cases of CNS manifestations of systemic vasculitis, seizure and new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disorders, including multiple sclerosis and optic neuritis, and peripheral demyelinating disorders, including Guillain-Barr√© syndrome.  Care should be exercised when considering the use of these agents in patients with neurologic disorders and discontinuing the agent is recommended if these disorders develop during therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7553, 0, 'Infliximab', 'Tuberculosis', 'Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving TNF blocking agents, including patients who have previously received treatment for latent or active tuberculosis.  Cases of active tuberculosis have also occurred in patients being treated with these agents during treatment for latent tuberculosis.  Prior to initiating TNF blocking agents, patients should be screened for latent tuberculosis infection with a tuberculin skin test and periodically during therapy.  Patients testing positive in tuberculosis screening should be treated by standard medical practice prior to therapy with TNF blocking agents.  Anti-tuberculosis therapy should also be considered prior to initiation of therapy in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection.  Tuberculosis should be strongly considered in patients who develop a new infection during treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7554, 0, 'Infliximab', 'Pulmonary Disease, Chronic Obstructive', 'In studies, patients with moderate to severe chronic obstructive pulmonary disease (COPD) treated with infliximab developed more malignancies, the majority of lung or head and neck origin than those treated with placebo.  Caution should be exercised when considering the use of infliximab in patients with moderate to severe COPD.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7555, 0, 'Infliximab', 'Hematologic Diseases', 'Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia, some with a fatal outcome, have been reported in patients treated with TNF blocking agents.  Caution should be exercised when treating patients who have ongoing or a history of significant hematologic abnormalities.  Discontinuation of therapy should be considered in patients with confirmed significant hematologic abnormalities.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7556, 0, 'Infliximab', 'Hepatitis B', 'The use of TNF blockers has been associated with reactivation of hepatitis B, in some cases fatal, in patients who were previously infected with the hepatitis B virus (HBV).  Therefore, screening for viral hepatitis should be performed in accordance with published guidelines before starting therapy with these agents.  Monitor patients at risk or with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation.  Prescribers should exercise caution in prescribing TNF blockers in patients previously infected with HBV.  It is recommended to monitor patients with evidence of current or prior HBV infection for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months following therapy.  In patients who develop HBV reactivation, therapy should be stopped and antiviral therapy with appropriate supportive treatment should be initiated.  The safety of resuming these agents after HBV reactivation is controlled is not known.  Therefore, prescribers should weigh the risks and benefits when considering resumption of therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7557, 0, 'Inotuzumab ozogamicin', 'Liver Diseases', 'Hepatotoxicity, including severe, life-threatening, and sometimes fatal hepatic veno-occlusive disease (VOD) may occur during or following treatment with inotuzumab ozogamicin.  The risk of VOD is greater in patients who underwent hematopoietic stem cell transplant (HSCT) after inotuzumab ozogamicin treatment, total bilirubin level greater than or equal to the ULN before HSCT, ongoing or prior liver disease, prior HSCT, increased age, later salvage lines, and a greater number of treatment cycles.  Patients who have experienced prior VOD or have serious ongoing hepatic liver disease (e.g., cirrhosis, nodular regenerative hyperplasia, active hepatitis) are at an increased risk for worsening of liver disease, including developing VOD, following treatment with inotuzumab ozogamicin.  Monitor closely for signs and symptoms of VOD; these may include elevations in total bilirubin, hepatomegaly (which may be painful), rapid weight gain, and ascites.  It is recommended to monitor liver tests in all patients, including ALT, AST, total bilirubin, and alkaline phosphatase, before and following each dose of inotuzumab ozogamicin.  Elevations of liver tests may require dosing interruption, dose reduction, or permanent discontinuation of treatment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7558, 0, 'Inotuzumab ozogamicin', 'Long QT Syndrome', 'The use of inotuzumab ozogamicin may cause increases in QT interval.  It is recommended to administer inotuzumab ozogamicin with caution in patients with a history or predisposition for QTc prolongation, those taking medications that are known to prolong QT interval, and in patients with electrolyte disturbances.  Obtain electrocardiograms and electrolytes values at baseline, after initiation of treatment, after initiation of drugs known to prolong QTc, and periodically thereafter as clinically indicated.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7559, 0, 'Inotuzumab ozogamicin', 'Kidney Diseases', 'The clearance of inotuzumab ozogamicin in patients with mild, moderate, or severe renal impairment was similar to patients with normal renal function.  Care should be exercised when administering this agent in patients with end stage renal disease with or without hemodialysis as the safety and efficacy of inotuzumab ozogamicin is unknown in this patient population.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7560, 0, 'Insulin aspart (aspart)', 'Liver Diseases', 'Insulin requirements may be diminished in patients with renal or hepatic impairment due to reduced insulin metabolism and, in the latter case, also to reduced capacity for gluconeogenesis.  Lower initial dosages may be appropriate, with careful monitoring of plasma glucose levels and dosing adjustments.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7561, 0, 'Insulin aspart (aspart)', 'Hypokalemia', 'Hypokalemia may commonly occur during treatment with insulin.  Use with caution in patients who may be particularly at risk of developing hypokalemia (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7562, 0, 'Insulin aspart (aspart)', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7563, 0, 'Anagrelide', 'Heart Diseases', 'The use of anagrelide may produce a positive inotropic effect, vasodilation, tachycardia, palpitations, and congestive heart failure.  Therapy with anagrelide should be administered cautiously in patients with cardiac disease.  A cardiovascular examination is recommended prior to beginning therapy with anagrelide.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7564, 0, 'Anagrelide', 'Liver Diseases', 'Anagrelide undergoes extensive metabolism in the liver, with less than 1% recovered unchanged in the urine.  Therapy with anagrelide should be administered cautiously in patients with liver disease (bilirubin, SGOT, or other liver measurements greater than 1.5 times normal) and only when the benefits outweigh the risks.  Monitoring for signs of liver toxicity is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7565, 0, 'Anagrelide', 'Kidney Diseases', 'The use of anagrelide has been rarely associated with renal failure most often in patients with serum creatinine values greater than 2.0.  Therapy with anagrelide should be administered cautiously in patients with renal dysfunction.  Monitoring for signs of renal toxicity is recommended in these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7566, 0, 'Anagrelide', 'Respiratory Insufficiency', 'The use of anagrelide may cause interstitial lung diseases, including allergic alveolitis, eosinophilic pneumonia, and interstitial pneumonitis.  The symptoms may present as progressive dyspnea with lung infiltrations.  Close monitoring should be exercised when using this agent in patients with pulmonary dysfunction.  It is recommended to discontinue anagrelide and evaluate the patient if symptoms of pulmonary toxicity occur.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7567, 0, 'Insulin degludec', 'Liver Diseases', 'Insulin requirements may be diminished in patients with renal or hepatic impairment due to reduced insulin metabolism and, in the latter case, also to reduced capacity for gluconeogenesis.  Lower initial dosages may be appropriate, with careful monitoring of plasma glucose levels and dosing adjustments.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7568, 0, 'Insulin degludec', 'Hypokalemia', 'Hypokalemia may commonly occur during treatment with insulin.  Use with caution in patients who may be particularly at risk of developing hypokalemia (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7569, 0, 'Insulin degludec', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7570, 0, 'Insulin glulisine', 'Liver Diseases', 'Insulin requirements may be diminished in patients with renal or hepatic impairment due to reduced insulin metabolism and, in the latter case, also to reduced capacity for gluconeogenesis.  Lower initial dosages may be appropriate, with careful monitoring of plasma glucose levels and dosing adjustments.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7571, 0, 'Insulin glulisine', 'Hypokalemia', 'Hypokalemia may commonly occur during treatment with insulin.  Use with caution in patients who may be particularly at risk of developing hypokalemia (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7572, 0, 'Insulin glulisine', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7573, 0, 'Insulin human (inhalation, rapid acting)', 'Asthma', 'The use of inhaled insulin is contraindicated in patients with chronic lung disease such as asthma and COPD.  Acute bronchospasm has been observed after an inhaled insulin dosage.  Prior to initiating therapy with an inhaled insulin product, it is recommended to evaluate all patients medical history, physical examination and spirometry (FEV1) to identify potential underlying lung disease.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7574, 0, 'Insulin human (inhalation, rapid acting)', 'Diabetic Ketoacidosis', 'Rapid acting inhaled insulin may predispose certain patients to develop diabetic ketoacidosis (DKA).  In clinical trials, subjects with type 1 diabetes receiving inhaled insulin were more likely to develop DKA than patients receiving comparator agents.  It is recommended to increase the frequency of glucose monitoring and to consider using an alternate route of administration, if appropriate, in patients at risk for DKA, such as patients with an acute illness or infections.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7575, 0, 'Insulin human (inhalation, rapid acting)', 'Lung Neoplasms', 'In clinical trials, lung cancer was observed in smoker and non-smoker patients using inhaled insulin.  In patients with active lung cancer, a prior history of lung cancer, or in patients at risk for lung cancer, it is recommended to consider whether the benefits of inhaled insulin use outweigh this potential risk.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7576, 0, 'Insulin human (inhalation, rapid acting)', 'Liver Diseases', 'Insulin requirements may be diminished in patients with renal or hepatic impairment due to reduced insulin metabolism and, in the latter case, also to reduced capacity for gluconeogenesis.  Lower initial dosages may be appropriate, with careful monitoring of plasma glucose levels and dosing adjustments.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7577, 0, 'Insulin human (inhalation, rapid acting)', 'Hypokalemia', 'Hypokalemia may commonly occur during treatment with insulin.  Use with caution in patients who may be particularly at risk of developing hypokalemia (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7578, 0, 'Insulin human (inhalation, rapid acting)', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7579, 0, 'Insulin human', 'Liver Diseases', 'Insulin requirements may be diminished in patients with renal or hepatic impairment due to reduced insulin metabolism and, in the latter case, also to reduced capacity for gluconeogenesis.  Lower initial dosages may be appropriate, with careful monitoring of plasma glucose levels and dosing adjustments.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7580, 0, 'Insulin human', 'Hypokalemia', 'Hypokalemia may commonly occur during treatment with insulin.  Use with caution in patients who may be particularly at risk of developing hypokalemia (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7581, 0, 'Insulin human', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7582, 0, 'Insulin human (isophane)', 'Liver Diseases', 'Insulin requirements may be diminished in patients with renal or hepatic impairment due to reduced insulin metabolism and, in the latter case, also to reduced capacity for gluconeogenesis.  Lower initial dosages may be appropriate, with careful monitoring of plasma glucose levels and dosing adjustments.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7583, 0, 'Insulin human (isophane)', 'Hypokalemia', 'Hypokalemia may commonly occur during treatment with insulin.  Use with caution in patients who may be particularly at risk of developing hypokalemia (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7584, 0, 'Insulin human (isophane)', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7585, 0, 'Interferon alfa-2a, Recombinant', 'Kidney Diseases', 'Proteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy.  Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported.  Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction.  Renal function should be evaluated in all patients before initiation of interferon- alfa therapy.  In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance.  A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7586, 0, 'Interferon alfa-2a, Recombinant', 'Autoimmune Diseases', 'Antiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis.  Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7587, 0, 'Interferon alfa-2a, Recombinant', 'Liver Diseases', 'Dose-related increases in liver transaminase levels occur frequently during interferon-alfa therapy.  Changes in LDH and alkaline phosphatase have been reported, primarily in patients with preexisting hepatic impairment.  Patients with autoimmune hepatitis who have received interferon-alfa have experienced severe, life-threatening exacerbation of their disease.  Therapy with interferon-alfa should be administered cautiously in patients with liver disease and should not be initiated in patients with autoimmune hepatitis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7588, 0, 'Interferon alfa-2a, Recombinant', 'Heart Diseases', 'Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy.  Therapy with interferons should be administered with caution in patients with compromised cardiac function.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7589, 0, 'Interferon alfa-2a, Recombinant', 'Central Nervous System Diseases', 'Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons.  Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7590, 0, 'Interferon alfa-2a, Recombinant', 'Depressive Disorder', 'Interferons (alfa or beta) can induce depression and suicidal behavior.  Suicidal attempts and suicides have been reported.  Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression.  Clinical monitoring of psychological status is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7591, 0, 'Interferon alfa-2a, Recombinant', 'Hypothyroidism', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients administered interferons.  Therapy with interferons should be administered cautiously to patients with thyroid dysfunction.  If thyroid control cannot be maintained within normal limits with medication, interferon-alfa should be discontinued.  Clinical monitoring of thyroid function is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7592, 0, 'Interferon alfa-2a, Recombinant', 'Diabetes Mellitus', 'Flu-like symptoms frequently associated with interferon-alfa therapy can precipitate ketoacidosis in diabetic patients.  Therapy with interferon alfa should be administered cautiously in patients with diabetes mellitus.  Clinical monitoring of blood glucose concentrations and anti-diabetic therapy is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7593, 0, 'Interferon alfa-2a, Recombinant', 'Bone Marrow Failure Disorders', 'Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression.  Leukopenia is the primary manifestation.  Thrombocytopenia and anemia occur less frequently.  Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7594, 0, 'Interferon alfa-2a, Recombinant', 'Peripheral Nervous System Diseases', 'Paresthesia and numbness have been reported during interferon therapy.  Therapy with interferons should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7595, 0, 'Insulin human (zinc)', 'Liver Diseases', 'Insulin requirements may be diminished in patients with renal or hepatic impairment due to reduced insulin metabolism and, in the latter case, also to reduced capacity for gluconeogenesis.  Lower initial dosages may be appropriate, with careful monitoring of plasma glucose levels and dosing adjustments.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7596, 0, 'Insulin human (zinc)', 'Hypokalemia', 'Hypokalemia may commonly occur during treatment with insulin.  Use with caution in patients who may be particularly at risk of developing hypokalemia (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7597, 0, 'Insulin human (zinc)', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7598, 0, 'Interferon alfa-2b', 'Kidney Diseases', 'Proteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy.  Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported.  Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction.  Renal function should be evaluated in all patients before initiation of interferon- alfa therapy.  In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance.  A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7599, 0, 'Interferon alfa-2b', 'Autoimmune Diseases', 'Antiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis.  Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7600, 0, 'Interferon alfa-2b', 'Liver Diseases', 'Dose-related increases in liver transaminase levels occur frequently during interferon-alfa therapy.  Changes in LDH and alkaline phosphatase have been reported, primarily in patients with preexisting hepatic impairment.  Patients with autoimmune hepatitis who have received interferon-alfa have experienced severe, life-threatening exacerbation of their disease.  Therapy with interferon-alfa should be administered cautiously in patients with liver disease and should not be initiated in patients with autoimmune hepatitis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7601, 0, 'Interferon alfa-2b', 'Heart Diseases', 'Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy.  Therapy with interferons should be administered with caution in patients with compromised cardiac function.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7602, 0, 'Interferon alfa-2b', 'Central Nervous System Diseases', 'Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons.  Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7603, 0, 'Interferon alfa-2b', 'Depressive Disorder', 'Interferons (alfa or beta) can induce depression and suicidal behavior.  Suicidal attempts and suicides have been reported.  Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression.  Clinical monitoring of psychological status is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7604, 0, 'Interferon alfa-2b', 'Hypothyroidism', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients administered interferons.  Therapy with interferons should be administered cautiously to patients with thyroid dysfunction.  If thyroid control cannot be maintained within normal limits with medication, interferon-alfa should be discontinued.  Clinical monitoring of thyroid function is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7605, 0, 'Interferon alfa-2b', 'Colitis', 'Fatal and nonfatal ulcerative or hemorrhagic/ischemic colitis have been observed within 12 weeks of the start of alpha interferon treatment.  Abdominal pain, bloody diarrhea, and fever are the typical manifestations.  Treatment should be discontinued immediately in patients who develop these signs and symptoms.  The colitis usually resolves within 1 to 3 weeks of discontinuation of alpha interferons.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7606, 0, 'Interferon alfa-2b', 'Diabetes Mellitus', 'Flu-like symptoms frequently associated with interferon-alfa therapy can precipitate ketoacidosis in diabetic patients.  Therapy with interferon alfa should be administered cautiously in patients with diabetes mellitus.  Clinical monitoring of blood glucose concentrations and anti-diabetic therapy is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7607, 0, 'Interferon alfa-2b', 'Bone Marrow Failure Disorders', 'Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression.  Leukopenia is the primary manifestation.  Thrombocytopenia and anemia occur less frequently.  Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7608, 0, 'Interferon alfa-2b', 'Peripheral Nervous System Diseases', 'Paresthesia and numbness have been reported during interferon therapy.  Therapy with interferons should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7609, 0, 'Anakinra', 'Infections', 'Anakinra has been associated with an increased incidence of serious infections in clinical trials in rheumatoid arthritis (RA).  RA therapy should be discontinued if a patient develops a serious infection.  In neonatal-onset multisystem inflammatory disease (NOMID) and deficiency of interleukin-1 receptor antagonist (DIRA) patients treated with anakinra, the risk of a disease flare when discontinuing this drug should be weighed against the potential risk of continued therapy.  Anakinra should not be started in patients with active infections.  Safety and efficacy have not been evaluated in immunosuppressed patients or in patients with chronic infections; caution is recommended when using anakinra in these patients.Drugs that affect the immune system by blocking tumor necrosis factor have been associated with an increased risk of reactivation of latent tuberculosis; it is possible that taking drugs that block interleukin-1 (such as anakinra) increases the risk of tuberculosis or other atypical or opportunistic infections.  The current US CDC guidelines should be followed both to evaluate for and to treat possible latent tuberculosis before starting therapy with anakinra.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7610, 0, 'Anakinra', 'Liver Diseases', 'No formal studies have been conducted examining the pharmacokinetics of anakinra administered subcutaneously in patients with hepatic dysfunction.  Caution is recommended when using anakinra in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7611, 0, 'Anakinra', 'Neutropenia', 'The use of anakinra has been associated with a decrease in neutrophil counts.  Neutrophil counts should be assessed prior to initiating therapy and while receiving therapy, monthly for 3 months and thereafter quarterly for up to 1 year.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7612, 0, 'Anakinra', 'Kidney Diseases', 'Anakinra is substantially excreted by the kidney.  The risk of toxic reactions to this drug may be greater in patients with impaired renal function.  Administration of the prescribed dose every other day should be considered for patients who have severe renal dysfunction or end-stage renal disease (defined as CrCl less than 30 mL/min [as estimated from serum creatinine levels]).  Caution should be exercised when using anakinra in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7613, 0, 'Insulin lispro', 'Liver Diseases', 'Insulin requirements may be diminished in patients with renal or hepatic impairment due to reduced insulin metabolism and, in the latter case, also to reduced capacity for gluconeogenesis.  Lower initial dosages may be appropriate, with careful monitoring of plasma glucose levels and dosing adjustments.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7614, 0, 'Insulin lispro', 'Hypokalemia', 'Hypokalemia may commonly occur during treatment with insulin.  Use with caution in patients who may be particularly at risk of developing hypokalemia (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7615, 0, 'Insulin lispro', 'Hypoglycemia', 'Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents.  Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7616, 0, 'Interferon alfacon-1', 'Kidney Diseases', 'Proteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy.  Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported.  Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction.  Renal function should be evaluated in all patients before initiation of interferon- alfa therapy.  In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance.  A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7617, 0, 'Interferon alfacon-1', 'Autoimmune Diseases', 'Antiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis.  Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7618, 0, 'Interferon alfacon-1', 'Liver Diseases', 'Dose-related increases in liver transaminase levels occur frequently during interferon-alfa therapy.  Changes in LDH and alkaline phosphatase have been reported, primarily in patients with preexisting hepatic impairment.  Patients with autoimmune hepatitis who have received interferon-alfa have experienced severe, life-threatening exacerbation of their disease.  Therapy with interferon-alfa should be administered cautiously in patients with liver disease and should not be initiated in patients with autoimmune hepatitis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7619, 0, 'Interferon alfacon-1', 'Heart Diseases', 'Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy.  Therapy with interferons should be administered with caution in patients with compromised cardiac function.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7620, 0, 'Interferon alfacon-1', 'Central Nervous System Diseases', 'Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons.  Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7621, 0, 'Interferon alfacon-1', 'Depressive Disorder', 'Interferons (alfa or beta) can induce depression and suicidal behavior.  Suicidal attempts and suicides have been reported.  Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression.  Clinical monitoring of psychological status is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7622, 0, 'Interferon alfacon-1', 'Hypothyroidism', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients administered interferons.  Therapy with interferons should be administered cautiously to patients with thyroid dysfunction.  If thyroid control cannot be maintained within normal limits with medication, interferon-alfa should be discontinued.  Clinical monitoring of thyroid function is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7623, 0, 'Interferon alfacon-1', 'Diabetes Mellitus', 'Flu-like symptoms frequently associated with interferon-alfa therapy can precipitate ketoacidosis in diabetic patients.  Therapy with interferon alfa should be administered cautiously in patients with diabetes mellitus.  Clinical monitoring of blood glucose concentrations and anti-diabetic therapy is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7624, 0, 'Interferon alfacon-1', 'Bone Marrow Failure Disorders', 'Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression.  Leukopenia is the primary manifestation.  Thrombocytopenia and anemia occur less frequently.  Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7625, 0, 'Interferon alfacon-1', 'Peripheral Nervous System Diseases', 'Paresthesia and numbness have been reported during interferon therapy.  Therapy with interferons should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7626, 0, 'Interferon beta-1a', 'Heart Diseases', 'Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy.  Therapy with interferons should be administered with caution in patients with compromised cardiac function.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7627, 0, 'Interferon beta-1a', 'Central Nervous System Diseases', 'Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons.  Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7628, 0, 'Interferon beta-1a', 'Depressive Disorder', 'Interferons (alfa or beta) can induce depression and suicidal behavior.  Suicidal attempts and suicides have been reported.  Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression.  Clinical monitoring of psychological status is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7629, 0, 'Interferon beta-1a', 'Liver Diseases', 'Severe hepatic injury, including hepatitis, autoimmune hepatitis, cases of hepatic failure and asymptomatic transient increases in the concentrations of serum transaminases, have been reported in patients treated with beta interferons.  In some cases, these events have occurred in the presence of other drugs that have been associated with hepatic injury.  The potential risk of these agents used in combination with known hepatotoxic drugs or other products (e.g., alcohol) should be considered before starting therapy, or before starting hepatotoxic drugs.  Patients should be monitored for signs of hepatic injury, including the regular monitoring of liver function tests, and discontinuation of therapy should be considered if serum transaminase levels significantly increase or if hepatic injury occurs.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7630, 0, 'Iodide I-123', 'Kidney Diseases', 'Sodium iodide is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7631, 0, 'Inulin', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7632, 0, 'Inulin', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7633, 0, 'Interferon gamma-1b', 'Heart Diseases', 'Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy.  Therapy with interferons should be administered with caution in patients with compromised cardiac function.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7634, 0, 'Interferon gamma-1b', 'Central Nervous System Diseases', 'Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons.  Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7635, 0, 'Interferon gamma-1b', 'Bone Marrow Failure Disorders', 'Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression.  Leukopenia is the primary manifestation.  Thrombocytopenia and anemia occur less frequently.  Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7636, 0, 'Interferon alfa-n3', 'Kidney Diseases', 'Proteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy.  Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported.  Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction.  Renal function should be evaluated in all patients before initiation of interferon- alfa therapy.  In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance.  A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7637, 0, 'Interferon alfa-n3', 'Autoimmune Diseases', 'Antiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis.  Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7638, 0, 'Interferon alfa-n3', 'Liver Diseases', 'Dose-related increases in liver transaminase levels occur frequently during interferon-alfa therapy.  Changes in LDH and alkaline phosphatase have been reported, primarily in patients with preexisting hepatic impairment.  Patients with autoimmune hepatitis who have received interferon-alfa have experienced severe, life-threatening exacerbation of their disease.  Therapy with interferon-alfa should be administered cautiously in patients with liver disease and should not be initiated in patients with autoimmune hepatitis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7639, 0, 'Interferon alfa-n3', 'Heart Diseases', 'Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy.  Therapy with interferons should be administered with caution in patients with compromised cardiac function.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7640, 0, 'Interferon alfa-n3', 'Central Nervous System Diseases', 'Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons.  Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7641, 0, 'Interferon alfa-n3', 'Depressive Disorder', 'Interferons (alfa or beta) can induce depression and suicidal behavior.  Suicidal attempts and suicides have been reported.  Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression.  Clinical monitoring of psychological status is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7642, 0, 'Interferon alfa-n3', 'Hypothyroidism', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients administered interferons.  Therapy with interferons should be administered cautiously to patients with thyroid dysfunction.  If thyroid control cannot be maintained within normal limits with medication, interferon-alfa should be discontinued.  Clinical monitoring of thyroid function is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7643, 0, 'Interferon alfa-n3', 'Diabetes Mellitus', 'Flu-like symptoms frequently associated with interferon-alfa therapy can precipitate ketoacidosis in diabetic patients.  Therapy with interferon alfa should be administered cautiously in patients with diabetes mellitus.  Clinical monitoring of blood glucose concentrations and anti-diabetic therapy is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7644, 0, 'Interferon alfa-n3', 'Bone Marrow Failure Disorders', 'Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression.  Leukopenia is the primary manifestation.  Thrombocytopenia and anemia occur less frequently.  Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7645, 0, 'Interferon alfa-n3', 'Peripheral Nervous System Diseases', 'Paresthesia and numbness have been reported during interferon therapy.  Therapy with interferons should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7646, 0, 'Anastrozole', 'Cardiovascular Diseases', 'In studies of women with preexisting ischemic heart disease, an increased incidence of ischemic cardiovascular events was observed with the use of anastrozole.  Caution should be exercised when prescribing anastrozole to these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7647, 0, 'Anastrozole', 'Hypercholesterolemia', 'During a clinical trial, more patients receiving anastrozole were reported to have elevated serum cholesterol compared to patients receiving tamoxifen (9% versus 3.5%, respectively).  Caution should be taken when this agent is prescribed to these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7648, 0, 'Anastrozole', 'Liver Diseases', 'Anastrozole is extensively metabolized by the liver.  Analysis of the pharmacokinetic disposition of anastrozole in patients with hepatic cirrhosis indicates that dosage adjustments of anastrozole are not necessary in patients with mild to moderate hepatic impairment.  Clinical monitoring for toxicity associated with anastrozole therapy is recommended.  Therapy with anastrozole should be administered cautiously in patients with severe hepatic impairment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7649, 0, 'Anastrozole', 'Osteoporosis', 'Results from the clinical trial bone substudy at 12 and 24 months demonstrated that patients receiving anastrozole had a mean decrease in both lumbar spine and total hip bone mineral density (BMD) compared to baseline.  Caution should exercise when prescribing this agent to patients with a risk of fractures, such as the elderly and patients with osteoporosis.  Consider bone mineral density monitoring in patients treated with anastrozole.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7650, 0, 'Iodine (topical)', 'Thyroid Hormone Metabolism, Abnormal', 'Elevated serum iodine levels can lead to altered thyroid function and metabolic abnormalities in patients receiving oral iodine therapy as well as topical therapy.  Iodine should be used cautiously in patients with thyroid disorders.  Monitoring thyroid function is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7651, 0, 'Iodide I-131', 'Kidney Diseases', 'Sodium iodide is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7652, 0, 'Iodide I-131', 'Bone Marrow Failure Disorders', 'Sodium iodide-I-131 administered at doses used for thyroid chemotherapy induces myelosuppression including anemia, leukopenia, and thrombocytopenia.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Therapy with sodium iodide-I-131 should be administered cautiously in patients with compromised bone marrow reserve.  Clinical monitory of hematopoietic function is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7653, 0, 'Iodixanol', 'Hyperthyroidism', 'Reports of thyroid storm following the use of iodinated diagnostic agents in patients with hyperthyroidism or with an autonomously functioning thyroid nodule suggest that this additional risk be evaluated in such patients before the use of any contrast medium.  Some agents such as ioversol are contraindicated in symptomatic hyperthyroidism.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7654, 0, 'Iodixanol', 'Pheochromocytoma', 'Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution.  If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium.  The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7655, 0, 'Iodixanol', 'Anemia, Sickle Cell', 'Some contrast agents have shown to promote the phenomenon of sickling (blood cell rupture) in individuals who are homozygous for sickle cell disease when administered intravenously or intra- arterially.  Caution is advised.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7656, 0, 'Iodixanol', 'Multiple Myeloma', 'A definite risk exists in the use of intravascular contrast agents in patients who are known to have multiple myeloma.  In such cases, anuria has developed resulting in progressive uremia, renal failure and eventually death.  Although neither the contrast agent nor dehydration has separately proved to be the cause of anuria in myeloma, it has been speculated that the combination of both may be causative factors.  The risk in patients with myeloma is not a contraindication to the procedure; however, partial dehydration in the preparation of these patients for the examination is not recommended since this may predispose to precipitation of myeloma protein in the renal tubules.  Myeloma, which occurs most commonly in persons over 40, should be considered before instituting intravascular administration of contrast agents.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7657, 0, 'Iodixanol', 'Myasthenia Gravis', 'The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.  Caution is advised when using these agents in patients with this condition.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7658, 0, 'Iodixanol', 'Kidney Diseases', 'In patients with advanced renal disease, iodinated contrast media should be used with caution, and only when the need for the examination dictates, since the excretion of the medium may be impaired.  Patients with combined renal and hepatic disease, severe hypertension or congestive heart failure, and those with recent renal transplant may present an additional risk.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7659, 0, 'Iodixanol', 'Hypersensitivity', 'Iodixanol can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis.  Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock.  Most severe reactions develop shortly after the start of the injection (within 3 minutes), but reactions can occur up to hours later.  There is an increased risk in patients with a history of a previous reaction to a contrast agent, and known allergies (i.e., bronchial asthma, drug, or food allergies) or other hypersensitivities.  Premedication with antihistamines or corticosteroids does not prevent serious life-threatening reactions, but may reduce both their incidence and severity.  Obtain a history of allergy, hypersensitivity, or hypersensitivity reactions to iodinated contrast agents and always have emergency resuscitation equipment and trained personnel available prior to iodixanol administration.  Monitor all patients for hypersensitivity reactions.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7660, 0, 'Iobenguane (I-123)', 'Hypertension', 'Iobenguane I-123 may increase release of norepinephrine from chromaffin granules and produce a transient episode of hypertension.  It is recommended to assess the patient''s pulse and blood pressure before and intermittently for 30 minutes after iobenguane I-123 administration.  Care should be exercised when using this agent in patients with hypertension.  Prior to Iobenguane I-123 administration, ensure emergency cardiac and anti-hypertensive treatments are readily available.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7661, 0, 'Iobenguane (I-123)', 'Parkinson Disease', 'Individuals with conditions that affect the sympathetic nervous system, e.g., Parkinsonian syndromes such as Parkinson''s disease or multiple system atrophy, may show decreased cardiac uptake of iobenguane I-123 independent of heart disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7662, 0, 'Iobenguane (I-123)', 'Kidney Diseases', 'Iobenguane I-123 is cleared by the kidneys and is not dialyzable.  When iobenguane I-123 is used in patients with severe renal impairment, the radiation dose may be increased due to delayed elimination of the drug which may also reduce the target to background rations and decrease the quality of scintigraphic images.  Care should be exercised when using this agent in patients with severe renal impairment as the safety and efficacy have not been established in these patients.  It is recommended to consider assessment of renal function in patients prior to iobenguane I-123 administration.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7663, 0, 'Iopromide', 'Myasthenia Gravis', 'The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.  Caution is advised when using these agents in patients with this condition.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7664, 0, 'Ipecac', 'Pneumonia, Aspiration', 'Ipecac induces vomiting of gastrointestinal contents that can be aspirated.  Therapy with ipecac should not be administered to patients who are less than fully conscious, severely intoxicated, in shock, having seizures, or lack gag reflexes.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7665, 0, 'Ipecac', 'Cardiomyopathies', 'Ipecac may be absorbed if vomiting does not take place.  Cardiotoxicity such as tachycardia, hypotension, dyspnea, ECG changes or arrhythmia have occurred.  Chronic use to induce vomiting by patients with eating disorders has resulted in myocarditis, cardiac arrest and failure.  Therapy with ipecac should be administered cautiously in patients with or predisposition to cardiovascular dysfunction.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7666, 0, 'Ipecac', 'Vascular Diseases', 'Ipecac induced vomiting can increase blood pressure.  Vomiting and retching associated with ipecac therapy may increase the risk of hemorrhage in patients with sclerotic or other pathologic changes in blood vessels.  Therapy with ipecac should be administered cautiously in patients with altered vascular physiology.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7667, 0, 'Ioxilan', 'Pheochromocytoma', 'Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution.  If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium.  The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7668, 0, 'Ioxilan', 'Kidney Diseases', 'In patients with advanced renal disease, iodinated contrast media should be used with caution, and only when the need for the examination dictates, since the excretion of the medium may be impaired.  Patients with combined renal and hepatic disease, severe hypertension or congestive heart failure, and those with recent renal transplant may present an additional risk.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7669, 0, 'Ioversol', 'Hyperthyroidism', 'Reports of thyroid storm following the use of iodinated diagnostic agents in patients with hyperthyroidism or with an autonomously functioning thyroid nodule suggest that this additional risk be evaluated in such patients before the use of any contrast medium.  Some agents such as ioversol are contraindicated in symptomatic hyperthyroidism.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7670, 0, 'Ioversol', 'Pheochromocytoma', 'Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution.  If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium.  The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7671, 0, 'Ioversol', 'Anemia, Sickle Cell', 'Some contrast agents have shown to promote the phenomenon of sickling (blood cell rupture) in individuals who are homozygous for sickle cell disease when administered intravenously or intra- arterially.  Caution is advised.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7672, 0, 'Ioversol', 'Myasthenia Gravis', 'The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.  Caution is advised when using these agents in patients with this condition.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7673, 0, 'Ioversol', 'Asthma', 'Iodinated contrast media such as ioversol, can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis and anaphylactic shock.  Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock.  Most severe reactions develop shortly after the start of the injection (e.g.  within 1 to 3 minutes), but delayed reactions may occur.  There is an increased risk in patients with a history of a previous reaction to contrast agent, and known allergies (i.e., bronchial asthma, drug, or food allergies), and other hypersensitivities.  Caution is advised on these patients.  Premedication with antihistamines or corticosteroids to avoid or minimize possible allergic reactions may reduce both their incidence and severity.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7674, 0, 'Ioversol', 'Acute Kidney Injury', 'Acute kidney injury, including renal failure, may occur after ioversol administration.  Risk factors include preexisting renal impairment, dehydration, diabetes, congestive heart failure, advanced vascular disease, multiple myeloma, elderly age, and concomitant use of nephrotoxic or diuretic medications.  The lowest dose of ioversol should be used in patients with renal impairment and other risk factors.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7675, 0, 'Ioversol', 'Cardiovascular Diseases', 'Life-threatening or fatal cardiovascular reactions have occurred with the use of ioversol, including cardiac arrest, hypotensive collapse and shock.  Most deaths have occurred following 10 minutes of the injection, and cardiovascular disease has been identified as the main underlying factor.  Additionally, ioversol increases the circulatory osmotic load and may induce acute or delayed hemodynamic disturbances in patients with congestive heart failure, and severely impaired renal function with or without hepatic disease.  Caution should be used when using ioversol in these patients and the lowest dose possible should be used.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7676, 0, 'Ipratropium', 'Anticholinergic Syndrome', 'Aclidinium, ipratropium, umeclidinium, and tiotropium are anticholinergic agents.  Although systemic effects are uncommon due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa, worsening of urinary retention or angle-closure glaucoma has been reported.  Increased intraocular pressure and precipitation or exacerbation of angle-closure glaucoma may also occur due to inadvertent contact of the eye with aerosolized or nebulized drug.  Accordingly, therapy with quaternary ammonium compounds should be administered cautiously in patients with urinary retention/obstruction or angle-closure glaucoma.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation or use of a mouthpiece rather than face mask during nebulization.  Patients should be advised to contact their physician if they experience urinary difficulty (especially in patients with prostatic hyperplasia or bladder neck obstruction); or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7677, 0, 'Ipratropium', 'Tachycardia', 'Cases of supraventricular tachycardia and atrial fibrillation have been reported with the use of inhaled anticholinergic agents in patients with COPD/Asthma.  Care and monitoring of cardiac function is recommended when prescribing these agents to patients at risk.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7678, 0, 'Ipratropium', 'Liver Failure', 'Ipratropium has not been studied in patients with hepatic or renal insufficiency.  Therapy with this agent should be used with caution in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7679, 0, 'Ipilimumab', 'Colitis', 'Ipilimumab can cause immune-mediated colitis, which may be fatal.  CMV infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis; repeating infectious workup should be considered in these patients to exclude alternative etiologies.  Ipilimumab should be withheld or permanently discontinued depending on severity of colitis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7680, 0, 'Ipilimumab', 'Dermatitis', 'Ipilimumab can cause immune-mediated rash or dermatitis (including bullous and exfoliative dermatitis, Stevens-Johnson syndrome [SJS], toxic epidermal necrolysis [TEN], and drug rash with eosinophilia and systemic symptoms [DRESS]).  Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate non-bullous/exfoliative rashes.  Ipilimumab should be withheld for suspected SJS, TEN, or DRESS and permanently discontinued for confirmed SJS, TEN, or DRESS.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7681, 0, 'Ipilimumab', 'Endocrine System Diseases', 'Immune-mediated endocrinopathies, including severe to life-threatening cases, have occurred with ipilimumab therapy.  It is recommended to monitor for signs/symptoms that may be clinical manifestations of underlying immune-mediated adverse reactions.  Clinical chemistries (including adrenocorticotropic hormone [ACTH] level and thyroid function) should be evaluated at baseline and before each dose.  Medical management should be started promptly, including specialty consultation as appropriate.  Ipilimumab should be withheld or permanently discontinued depending on severity of endocrinopathies.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7682, 0, 'Ipilimumab', 'Hepatitis', 'Ipilimumab can cause immune-mediated adverse reactions, which may be severe or fatal.  Immune-mediated hepatitis has occurred with ipilimumab therapy.  It is recommended to monitor for signs/symptoms that may be clinical manifestations of underlying immune-mediated adverse reactions.  Clinical chemistries (including liver enzymes) should be evaluated at baseline and before each dose.  Ipilimumab should be withheld or permanently discontinued depending on severity of hepatitis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7683, 0, 'Ipilimumab', 'Graft vs Host Disease', 'Fatal or serious graft-versus-host disease (GVHD) can occur in patients who receive ipilimumab either before or after allogeneic hematopoietic stem cell transplantation (HSCT).  These complications may occur despite intervening therapy between cytotoxic T-lymphocyte antigen 4 (CTLA-4) receptor blocking antibody and allogeneic HSCT.  It is recommended to monitor patients closely for evidence of GVHD and intervene promptly.  The benefit versus risks of treatment with ipilimumab after allogeneic HSCT should be considered.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7684, 0, 'Ipilimumab', 'Immune System Diseases', 'Ipilimumab can cause immune-mediated adverse reactions, which may be severe or fatal.  Immune-mediated adverse reactions can occur in any organ system or tissue.  Care should be exercised when using ipilimumab in patients with preexisting immune system disorders (e.g., ulcerative colitis, Crohn''s disease, lupus).  It is recommended to monitor for signs/symptoms that may be clinical manifestations of underlying immune-mediated adverse reactions.  Clinical chemistries (including liver enzymes, creatinine, adrenocorticotropic hormone [ACTH] level, and thyroid function) should be evaluated at baseline and before each dose.  Medical management should be started promptly, including specialty consultation as appropriate.  Ipilimumab should be withheld or permanently discontinued depending on severity.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7685, 0, 'Ipilimumab', 'Eye Diseases', 'Ipilimumab can cause immune-mediated adverse reactions, which may be severe or fatal.  It is recommended to monitor for signs/symptoms that may be clinical manifestations of underlying immune-mediated adverse reactions.  Ipilimumab should be permanently discontinued for a Grade 2, 3, or 4 ophthalmologic adverse reaction that does not improve to Grade 1 within 2 weeks while receiving topical therapy or if systemic therapy is required.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7686, 0, 'Ipilimumab', 'Hepatic Insufficiency', 'Care should be exercised when using ipilimumab in patients with moderate (total bilirubin greater than 1.5 to 3 times the upper limit of normal [1.5 to 3 x ULN] and any AST) or severe (total bilirubin greater than 3 x ULN and any AST) liver dysfunction as ipilimumab has not been studied in these patients.  Mild liver dysfunction (total bilirubin greater than 1 to 1.5 x ULN or AST greater than ULN) had no clinically significant effect on the clearance of ipilimumab.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7687, 0, 'Ipilimumab', 'Pneumonia', 'Ipilimumab can cause immune-mediated pneumonitis.  Care should be exercised when using ipilimumab in patients with preexisting pulmonary impairment.  Ipilimumab should be withheld or permanently discontinued depending on severity of pneumonitis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7688, 0, 'Anidulafungin', 'Liver Diseases', 'Laboratory abnormalities in liver function tests have been observed in healthy volunteers and patients treated with echinocandins, and clinical hepatic abnormalities have occurred in some patients with serious underlying conditions who were receiving multiple concomitant medications with echinocandin therapy.  Isolated cases of significant hepatic dysfunction, hepatitis, or worsening hepatic failure have also been reported, although a causal relationship has not been established.  Therapy with echinocandins should be administered cautiously in patients with preexisting liver disease.  Liver function should be monitored regularly during therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7689, 0, 'Ipratropium (nasal)', 'Anticholinergic Syndrome', 'Aclidinium, ipratropium, umeclidinium, and tiotropium are anticholinergic agents.  Although systemic effects are uncommon due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa, worsening of urinary retention or angle-closure glaucoma has been reported.  Increased intraocular pressure and precipitation or exacerbation of angle-closure glaucoma may also occur due to inadvertent contact of the eye with aerosolized or nebulized drug.  Accordingly, therapy with quaternary ammonium compounds should be administered cautiously in patients with urinary retention/obstruction or angle-closure glaucoma.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation or use of a mouthpiece rather than face mask during nebulization.  Patients should be advised to contact their physician if they experience urinary difficulty (especially in patients with prostatic hyperplasia or bladder neck obstruction); or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7690, 0, 'Iron Dextran', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7691, 0, 'Iron Dextran', 'Liver Diseases', 'Iron is transported in plasma complexed to transferrin, a beta1-glycoprotein synthesized by the liver.  Iron is cleared from the plasma by the reticuloendothelial system (including liver) and excess stored as ferritin within the reticuloendothelial system and hepatocytes.  Therapy with iron dextran should be administered with extreme caution in patients with severe hepatic dysfunction.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7692, 0, 'Iron Dextran', 'Nervous System Diseases', 'Iron dextran has induced neurologic toxicity such as seizures, paresthesia, weakness, disorientation, and unconsciousness.  Therapy with iron dextran should be administered cautiously in patients with or predisposed to neurologic dysfunction.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7693, 0, 'Iron Dextran', 'Cardiomyopathies', 'Cardiac toxicity such as chest pain and tightness, shock, hypertension, tachycardia and arrhythmia have occurred during iron dextran therapy.  Hypotension and flushing have been reported and are thought to be infusion- rate related.  Adverse reactions experienced following therapy with iron dextran may exacerbate cardiovascular complications in patients with preexisting cardiovascular disease, caution is advised.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7694, 0, 'Iron Dextran', 'Hypersensitivity, Immediate', 'Hypersensitivity reactions, including anaphylaxis, have occurred after uneventful test doses as well as therapeutic doses of iron dextran injection, usually within the first several minutes of administration.  Iron dextran should be administered cautiously in patients with a history of significant allergies and/or asthma.  Epinephrine should be immediately available in the event of acute hypersensitivity reactions.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7695, 0, 'Iron Dextran', 'Arthritis, Rheumatoid', 'Patients with rheumatoid arthritis may have an acute exacerbation of joint pain and swelling following the administration of iron dextran.', '1', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7696, 0, 'Irinotecan', 'Bone Marrow Failure Disorders', 'Irinotecan induces myelosuppression, causing leukopenia, thrombocytopenia and anemia.  Deaths due to sepsis following severe neutropenia have been reported in patients treated with irinotecan.  Hold irinotecan if neutropenic fever occurs or if the absolute neutrophil count drops <1000/mm3.  After recovery to an absolute neutrophil count =1000/mm3, subsequent doses of irinotecan should be reduced.  Therapy with irinotecan should be administered cautiously in patients who have received previous irradiation therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7697, 0, 'Irinotecan', 'Liver Diseases', 'Irinotecan clearance is diminished in patients with hepatic impairment.  The magnitude of these effects is proportional to the degree of liver impairment as measured by elevations in total bilirubin and transaminase concentrations.  However, the tolerability of irinotecan in patients with hepatic dysfunction (bilirubin greater than 2 mg/dl) has not been assessed sufficiently, and no recommendations for dosing are made by the manufacturers.  Therapy with irinotecan should be administered cautiously to patients with or predisposed to compromised hepatic function.  Clinical monitoring of hepatic function is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7698, 0, 'Irinotecan', 'Kidney Diseases', 'The influence of renal impairment on the pharmacokinetics of irinotecan has not been evaluated.  Therefore, caution should be undertaken in patients with impaired renal function.  Irinotecan hydrochloride is not recommended for use in patients on dialysis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7699, 0, 'Irinotecan', 'Lung Diseases, Interstitial', 'Irinotecan can cause severe and fatal interstitial pulmonary disease (IPD).  Risk factors include preexisting-existing lung disease.  It is recommended to withhold treatment with irinotecan in patients with new or progressive dyspnea, cough, and fever, pending diagnostic evaluation and to discontinue treatment in patients with a confirmed diagnosis of IPD.  Exercise caution when using this agent in patients presenting symptoms of dyspnea and patients with pulmonary impairment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7700, 0, 'Irinotecan', 'Diarrhea', 'Irinotecan liposomal can cause severe and life-threatening diarrhea.  Do not administer Irinotecan liposomal to patients with bowel obstruction.  It is recommended to withhold treatment with irinotecan liposomal for Grade 2-4 diarrhea and to initiate appropriate clinical measures for diarrhea of any severity.  The dose of irinotecan liposomal should be reduced according to manufacturer indications following recovery to Grade 1 diarrhea.  Care should be exercised when using this agent in patients at risk of diarrhea episodes.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7701, 0, 'Irinotecan', 'Neutropenia', 'Irinotecan liposomal can cause severe or life-threatening neutropenia and fatal neutropenic sepsis.  In patients receiving irinotecan liposomal in combination with 5-FU and LV, the incidence of Grade 3 or 4 neutropenia and neutropenic fever/neutropenic sepsis was higher among Asian patients compared to White patients.  Individuals who are homozygous for the UGT1A1*28 allele are at increased risk for neutropenia.  It is recommended to monitor complete blood cell counts on Days 1 and 8 of every cycle and more frequently if clinically indicated and to withhold treatment if the absolute neutrophil count is below 1500/mm ^3 or if neutropenic fever occurs.  Therapy could be resumed when the ANC is 1500/mm^ 3 or above.  The dose of irinotecan liposomal should be reduced according to manufacturer indications for Grade 3-4 neutropenia or neutropenic fever following a recovery in subsequent cycles.  Care is recommended when using this agent in neutropenic patients and in those patients homozygous for the UGT1A1*28 allele.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7702, 0, 'Irinotecan', 'Liver Failure', 'The metabolism of irinotecan liposomal has not been evaluated.  Irinotecan is primary metabolized by the liver to a biologically active metabolite.  The pharmacokinetic disposition of irinotecan liposomal in patients with hepatic impairment has not been formally assessed.  Therapy with irinotecan liposomal should be administered cautiously to patients with or predisposed to compromised hepatic function.  Clinical monitoring of hepatic function is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7703, 0, 'Irbesartan', 'Diabetes Mellitus', 'The coadministration of some angiotensin II receptor blocker agents with aliskiren is contraindicated in patients with diabetes.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7704, 0, 'Irbesartan', 'Angioedema', 'The use of these agents is contraindicated in patients with a history of angioedema related to previous angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) therapy or in patients with hereditary angioedema.  Patients with a history of angioedema unrelated to these agents may be at increased risk of angioedema while receiving angiotensin II receptor (AR) antagonists.  Patients should be advised to immediately report any signs or symptoms suggestive of angioedema (swelling of face, extremities, eyes, lips, or tongue, or difficulty swallowing or breathing) and to stop taking the medication until otherwise directed by their physician.  Emergency therapy and/or measures to prevent airway obstruction are required for angioedema involving the tongue, glottis, or larynx.  Treatment with angiotensin II receptor (AR) antagonists should be discontinued permanently if angioedema develops in association with therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7705, 0, 'Irbesartan', 'Hypotension', 'Angiotensin II receptor (AR) antagonists can cause symptomatic hypotension in patients with an activated renin-angiotensin system, such as volume- and/or sodium-depleted patients.  Therapy with AR antagonists should be administered cautiously in such patients and in those predisposed to hypovolemic or hyponatremic states (e.g., patients on diuretic therapy, especially if high doses were used or if recently instituted; those on dietary salt restriction; renal dialysis patients).  Volume and/or sodium depletion should be corrected prior to initiating therapy with AR antagonists, and the patient should be hemodynamically stable.  Ideally, patients at risk for excessive hypotension should initiate AR antagonist therapy under close medical supervision, preferably with a lower dose, and followed closely for the first 2 weeks of treatment and whenever the dosage of AR antagonist or diuretic is increased.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7706, 0, 'Irbesartan', 'Heart Failure', 'Angiotensin II receptor (AR) antagonists can cause renal impairment in patients whose renal function depends on the activity of the renin-angiotensin-aldosterone system.  In addition, symptomatic hypotension can occur in susceptible individuals, which may compromise renal and myocardial perfusion.  In patients with severe congestive heart failure (CHF), treatment with AR antagonists has been associated with oliguria and/or progressive azotemia and, rarely, renal failure, myocardial ischemia, and death.  Therapy with AR antagonists should be initiated cautiously in patients with severe CHF, especially when accompanied by volume and/or sodium depletion.  In patients who experience a decline in renal function, discontinuation of AR antagonist therapy is usually not required provided there is symptomatic improvement of the heart failure and renal deterioration is well-tolerated.  Transient hypotension is also not a contraindication to further treatment with AR antagonists, since therapy can usually be reinstated without difficulty after blood pressure stabilizes.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7707, 0, 'Irbesartan', 'Hyperkalemia', 'Drugs that inhibit the renin-angiotensin, such as angiotensin II receptor antagonist system can cause hyperkalemia.  Concomitant use of these agents with drugs that increase potassium levels may increase the risk of hyperkalemia.  Use caution when using these agents together and monitor serum potassium periodically.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7708, 0, 'Irbesartan', 'Renal Artery Obstruction', 'In patients with bilateral renal artery stenosis or renal artery stenosis in a solitary kidney, angiotensin II receptor (AR) antagonists may reduce renal perfusion to a critically low level.  Increases in serum creatinine or blood urea nitrogen have been reported with ACE inhibitors, a class of drugs that also block the renin-angiotensin-aldosterone system.  Although there are no long-term data on the use of AR antagonists in patients with renal artery stenosis, a similar effect should be anticipated.  Renal function should be monitored closely for the first few weeks of therapy.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7709, 0, 'Irbesartan', 'Kidney Diseases', 'Changes in renal function including acute renal failure can be caused by drugs that inhibit the renin-angiotensin system and by diuretics.  Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion) may be at particular risk of developing acute renal failure with these agents.  Monitor renal function periodically in these patients.  Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function with these agents.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7710, 0, 'Irbesartan', 'Liver Diseases', 'Irbesartan is metabolized by the liver, and both parent drug and metabolites are eliminated by the kidney (20%) as well as by biliary excretion (80%).  Dosage adjustments are not necessary in patients with renal impairment unless they are also volume-depleted, in which case therapy should be initiated under medical supervision.  Likewise, patients with hepatic impairment or biliary obstruction generally do not require a dosage adjustment.  However, reduced dosages may be appropriate in patients with both renal and liver or biliary disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7711, 0, 'Isatuximab', 'Hepatic Insufficiency', 'The effect of moderate (total bilirubin >1.5 times to 3 times ULN and any AST) and severe (total bilirubin >3 times ULN and any AST) hepatic impairment on isatuximab pharmacokinetics is unknown.  Although no specific dose adjustments are recommended in this patient population, caution and monitoring is advised.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7712, 0, 'Isavuconazonium', 'Short Qt Syndrome', 'Isavuconazonium shortened the QTc interval in a concentration-related manner.  This drug is contraindicated in patients with familial short QT syndrome.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7713, 0, 'Isavuconazonium', 'Liver Diseases', 'The use of isavuconazonium has been associated with hepatic adverse reactions (e.g., elevations in ALT, AST, alkaline phosphatase, total bilirubin).  Cases of more severe hepatic reactions (including hepatitis, cholestasis, hepatic failure including death) have been reported during therapy in patients with serious underlying medical conditions (e.g., hematologic malignancy).  Liver-related laboratory tests should be evaluated at the start and during therapy.  Isavuconazonium has not been studied in patients with severe liver dysfunction (Child-Pugh C) and should be used in these patients only when the benefits outweigh the risk.  Clinical monitoring for drug-related side effects is recommended when treating patients with severe liver dysfunction.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7714, 0, 'Isocarboxazid', 'Cerebrovascular Disorders', 'The use of monoamine oxidase inhibitor (MAOI) antidepressants is contraindicated in patients with cerebrovascular or cardiovascular disease, including hypertension and congestive heart failure.  Nonspecific MAOIs inhibit the breakdown of pressor amines, the accumulation of which can precipitate hypertensive crises.  Intracranial hemorrhage and death have resulted in some cases.  MAOI antidepressants are also commonly associated with dose-related orthostatic hypotension, which occurs most frequently in patients with preexisting hypertension but may be minimized with slow, gradual titration.  Blood pressure should be monitored closely in all patients who receive MAOI therapy, and patients should be advised to stop taking the medication and seek medical attention immediately if signs and symptoms of a hypertensive reaction occur (e.g., occipital headache which may radiate frontally; palpitation; neck stiffness or soreness; nausea or vomiting; perspiration associated with fever or cold, clammy skin; mydriasis; photophobia; constricting chest pain).', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7715, 0, 'Isocarboxazid', 'Malignant Carcinoid Syndrome', 'The use of nonspecific monoamine oxidase inhibitors (MAOIs) is contraindicated in patients with carcinoid syndrome.  Nonspecific MAOIs inhibit the breakdown of pressor amines, including serotonin, and may exacerbate symptoms of the syndrome.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7716, 0, 'Isocarboxazid', 'Headache', 'The use of monoamine oxidase inhibitor (MAOI) antidepressants is contraindicated in patients with a history of headaches.  Nonspecific MAOIs inhibit the breakdown of pressor amines, the accumulation of which can precipitate hypertensive crises.  Intracranial hemorrhage and death have resulted in some cases.  Since headache may often be the first symptom of a hypertensive reaction during MAOI therapy, use of these agents is not recommended in patients who experience frequent or severe headaches.  MAOIs should be withdrawn promptly if headaches develop during treatment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7717, 0, 'Isocarboxazid', 'Hyperthyroidism', 'Nonspecific monoamine oxidase inhibitors (MAOIs) inhibit the breakdown of pressor amines, the accumulation of which can precipitate hypertensive crises.  Intracranial hemorrhage and death have resulted in some cases.  Therapy with nonspecific MAOIs should be administered cautiously in patients with hyperthyroidism, since these patients have an increased sensitivity to pressor amines.  Blood pressure should be monitored closely during therapy, and patients should be advised to stop taking the medication and seek medical attention immediately if signs and symptoms of a hypertensive reaction occur (e.g., occipital headache which may radiate frontally; palpitation; neck stiffness or soreness; nausea or vomiting; perspiration associated with fever or cold, clammy skin; mydriasis; photophobia; constricting chest pain).', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7718, 0, 'Isocarboxazid', 'Liver Diseases', 'The use of monoamine oxidase inhibitor (MAOI) antidepressants is contraindicated in patients with abnormal liver function tests or a history of liver disease.  A low incidence of altered liver function or hepatocellular jaundice has been reported in association with the use of MAOI antidepressants.  Periodic monitoring of liver function tests is recommended during prolonged and/or high-dose therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7719, 0, 'Isocarboxazid', 'Pheochromocytoma', 'The use of nonspecific monoamine oxidase inhibitors (MAOIs) is contraindicated in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas, that secrete pressor substances.  Nonspecific MAOIs inhibit the breakdown of pressor amines, the accumulation of which can precipitate hypertensive crises.  Intracranial hemorrhage and death have resulted in some cases.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7720, 0, 'Isocarboxazid', 'Kidney Diseases', 'The use of monoamine oxidase inhibitor (MAOI) antidepressants is contraindicated in patients with severe renal dysfunction.  These drugs may accumulate in plasma when renal function is impaired.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7721, 0, 'Isocarboxazid', 'Alcoholism', 'The use of monoamine oxidase inhibitors with alcohol or any other CNS depressants is contraindicated.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7722, 0, 'Isocarboxazid', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7723, 0, 'Isocarboxazid', 'Cardiovascular disease', 'The use of most monoamine oxidase inhibitors (MAOIs) is contraindicated in patients with diagnosed cardiovascular disease, hypertension, or confirmed or suspected cerebrovascular disorders.  These drugs can cause hypertensive crises, which sometimes can be fatal, and are characterized by occipital headache, palpitations, neck stiffness or soreness, nausea, sweating, dilated pupils and photophobia.  Intracranial bleeding has been reported in some cases in association with the increase in blood pressure.Normotensive patients receiving therapy with MAOIs need to have monitored their blood pressure frequently to detect any evidence of pressor response and treatment should be discontinued immediately if blood pressure increases or the patient reports symptoms such a headaches or palpitations.  Additionally, patients should be advised to avoid foods and drinks with high tyramine content such as cheese, sour cream, beer, liver, bananas and others, as these might trigger an hypertensive crisis.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7724, 0, 'Isocarboxazid', 'Kidney Failure, Chronic', 'The use of some monoamine oxidase inhibitors such as isocarboxazid and phenelzine, is contraindicated in patients with severe renal impairment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7725, 0, 'Isocarboxazid', 'Hypoglycemia', 'There is conflicting evidence regarding whether monoamine oxidase inhibitors (MAOIs) affect glucose metabolism or potentiate oral hypoglycemic agents.  Therapy with MAOIs should be administered cautiously in patients with diabetes.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7726, 0, 'Isocarboxazid', 'Parkinsonian Disorders', 'Nonspecific monoamine oxidase inhibitors (MAOIs) may increase the frequency and severity of signs and symptoms associated with parkinsonian syndrome.  Therapy with nonspecific MAOIs should be administered cautiously in patients with this disorder.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7727, 0, 'Isocarboxazid', 'Mental Disorders', 'Monoamine oxidase inhibitor (MAOI) antidepressants may cause excessive stimulation in hyperactive or schizophrenic patients.  Symptoms of psychosis may be aggravated in schizophrenia, particularly that with paranoid symptomatology.  Depressed patients, usually those with bipolar disorder, may experience a switch from depression to mania or hypomania.  Therapy with MAOI antidepressants should be administered cautiously in patients with hyperactive or hyperexcitable personalities, schizophrenia or bipolar disorder.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7728, 0, 'Isocarboxazid', 'Seizures', 'Monoamine oxidase inhibitor (MAOI) antidepressants may have variable effects on seizure threshold.  Decreased seizure frequency as well as increased frequency have been reported.  Therapy with MAOI antidepressants should be administered cautiously in patients with a history of seizures.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7729, 0, 'Isocarboxazid', 'Angina Pectoris', 'Monoamine oxidase inhibitors may have the capacity to suppress anginal pain that would otherwise serve as a warning of myocardial ischemia.  Caution is advised in patients with a history of angina or risk of myocardial infarction.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7730, 0, 'Isocarboxazid', 'Bipolar Disorder', 'A major depressive episode can be the initial presentation of bipolar disorder.  Patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder prior to initiating treatment with a monoamine oxidase inhibitor (MAOI).  This screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.  It should be noted that MAOIs antidepressants are not approved for use in treating bipolar depression.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7731, 0, 'Isocarboxazid', 'Diabetes Mellitus', 'Monoamine oxidase inhibitors can increase the sensitivity to insulin, and have contributed to hypoglycemic episodes in patients with diabetes.  Caution should be used when prescribing in diabetic patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7732, 0, 'Isocarboxazid', 'Hypotension', 'Hypotension has been observed during therapy with monoamine oxidase inhibitors.  These drugs should be used with caution, especially in patients with tendency towards hypotension or taking other drugs known to cause hypotension.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7733, 0, 'Isocarboxazid', 'Schizophrenia', 'Some monoamine oxidase inhibitors such as isocarboxazid and phenelzine, should be used cautiously in hyperactive and agitated patients, as well as schizophrenic patients, as these may cause excessive stimulation.  Additionally, activation of mania/hypomania has been reported in a small portion of patients with major affective disorders.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7734, 0, 'Iron sucrose', 'Hemoglobinopathies', 'There is no excretory mechanism for iron.  Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions.  Clinical monitoring of erythropoietic function and ferritin levels is recommended.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7735, 0, 'Iron sucrose', 'Hemochromatosis', 'Sucroferric oxyhydroxide contains iron and should be prescribed with caution in patients with a history of hemochromatosis or other diseases associated with iron accumulation.  Iron homeostasis should be closely monitored, and the medication discontinued in patients who develop iron overload.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7736, 0, 'Isoniazid', 'Liver Diseases', 'The use of isoniazid is contraindicated in patients with acute liver disease or a history of hepatic injury due to isoniazid.  Caution is advised when using the drug in patients with chronic liver disease or a history of alcoholism.  Isoniazid has been associated with severe and sometimes fatal hepatitis, which may occur even after many months of therapy.  In a US Public Health Service Surveillance Study of nearly 14,000 isoniazid patients, the incidence of hepatitis was 1.25%, of which 4.6% was fatal.  However, more recent studies have reported considerably lower rates when CDC guidelines for selection and monitoring of patients were followed.  Epidemiologic studies indicate an increased incidence with increasing age, alcohol use, and female gender.  As a precautionary measure, routine monitoring of serum transaminases (SGOT, SGPT) and bilirubin may be considered, although a transient and harmless increase in serum transaminase reportedly occurs in 10% to 20% of patients, usually in the first 3 months of therapy.  Patients should be advised to promptly discontinue isoniazid therapy and seek medical attention if they experience signs or symptoms suggestive of liver damage such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice.  Reinstitution of the drug should occur only after symptoms and laboratory abnormalities resolve, with low and gradually increasing dosages.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7737, 0, 'Isoniazid', 'Peripheral Nervous System Diseases', 'Isoniazid commonly causes dose-related peripheral neuropathy, which results from the depletion of pyridoxine in the presence of the drug.  The neuropathy is usually preceded by paresthesias of the feet and hands.  Therapy with isoniazid should be administered cautiously in patients with preexisting peripheral neuropathy or risk factors for developing the condition, such as malnutrition, diabetes and alcoholism.  Pyridoxine (vitamin B6) at a dosage of 10 to 50 mg/day may prevent or attenuate isoniazid-related peripheral neuropathy and is recommended for these patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7738, 0, 'Isoniazid', 'Diseases requiring hemodialysis', 'Isoniazid is substantially removed by hemodialysis and should be administered after dialysis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7739, 0, 'Isoniazid', 'Kidney Diseases', 'Isoniazid is metabolized primarily by acetylation and dehydrazination in the liver.  It is not significantly excreted by the kidney.  Dosage adjustments in renal impairment are generally not necessary except in slow acetylators with a creatinine clearance below 10 mL/min.  The rate of acetylation is genetically determined.  Approximately 50% of blacks and caucasians are slow acetylators, and the majority of Eskimos and Asians are rapid acetylators.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7740, 0, 'Isoprenaline', 'Tachycardia', 'The use of isoproterenol is contraindicated in patients with tachyarrhythmias; tachycardia or heart block caused by digitalis intoxication; ventricular arrhythmias which require inotropic therapy; and angina pectoris.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7741, 0, 'Isoprenaline', 'Dehydration', 'The use of sympathomimetic amines has been infrequently associated with significant hypotension especially in dehydrated patients secondary to the drug''s beta-2 mediated vasodilation.  Hypovolemia should be corrected, if possible, before administering sympathomimetic amines.  Blood pressure and ECG should be monitored at regular intervals.  Monitoring of cardiac output and pulmonary wedge pressure may also be desired.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7742, 0, 'Isoprenaline', 'Acidosis', 'Acidosis, hypoxia, and hypercapnia may reduce the effectiveness of sympathomimetic amines in raising blood pressure.  These conditions should be corrected before initiating therapy with sympathomimetic amines, if possible.  Monitoring the patients acid-base balance, carbon dioxide levels, and oxygen saturation is recommended.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7743, 0, 'Isotretinoin', 'Intracranial Hypertension', 'The use of retinoids has been associated with cases of pseudotumor cerebri (benign intracranial hypertension).  Early signs and symptoms include papilledema, headache, nausea and vomiting, and visual disturbances.  Patients who experience symptoms of this disorder while on retinoid therapy should be referred to a neurologist.  If the diagnosis is confirmed, the retinoid should be discontinued permanently.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7744, 0, 'Isotretinoin', 'Mental Disorders', 'The use of retinoids, primarily isotretinoin, has been associated with causing depression, psychosis and rarely, suicidal ideation.  Therapy with retinoids should be administered cautiously in patients with preexisting psychiatric conditions or depression.  In addition to withdrawal of therapy, evaluation and follow-up may be necessary in affected patients.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7745, 0, 'Isotretinoin', 'Osteoporosis', 'Isotretinoin may have a negative effect on bone mineral density in some patients.  Clinical trials have shown BMD declines in adolescents during a 20 week treatment.  Therefore, physicians should use caution when prescribing isotretinoin in patients with a history of childhood osteoporosis, osteomalacia, or other disorders of bone metabolism.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7746, 0, 'Isotretinoin', 'Hyperlipidemias', 'The use of retinoids is associated with elevations in serum triglycerides and cholesterol, and decreases in HDL.  In addition to cardiovascular risks, elevation of serum triglycerides to greater than 800 mg/dL has been associated with fatal fulminant pancreatitis.  Patients at increased risk for developing hypertriglyceridemia during retinoid therapy include those with diabetes mellitus, obesity, high alcohol consumption, or a family history of these conditions.  Blood lipid determinations should be performed prior to initiation of therapy and at 1- to 2- week intervals until the lipid response to the drug is established (usually 4 to 8 weeks).  Patients with preexisting hyperlipidemia may require closer monitoring during retinoid therapy, and adjustments made accordingly in their lipid-lowering regimen.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7747, 0, 'Isotretinoin', 'Liver Diseases', 'The use of retinoids has been associated with elevations in liver enzymes and toxic hepatitis.  Therapy with retinoids should be administered cautiously in patients with liver disease.  Monitoring liver enzymes is recommended in these patients.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7748, 0, 'Isosorbide mononitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7749, 0, 'Isosorbide mononitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7750, 0, 'Isosorbide mononitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7751, 0, 'Isosorbide mononitrate', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7752, 0, 'Isosorbide mononitrate', 'Intracranial Hypertension', 'Organic nitrates and nitrites can increase cerebrospinal fluid pressure.  Therapy with these agents should be administered cautiously, if at all, in patients with or at risk for intracranial hypertension, including those with cerebral hemorrhage, intracranial lesions, or recent head trauma.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7753, 0, 'Isosorbide mononitrate', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7754, 0, 'Isosorbide mononitrate', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7755, 0, 'Isradipine', 'Shock, Cardiogenic', 'In general, calcium channel blockers (CCBs) should not be used in patients with hypotension (systolic pressure < 90 mm Hg) or cardiogenic shock.  Due to potential negative inotropic and peripheral vasodilating effects, the use of CCBs may further depress cardiac output and blood pressure, which can be detrimental in these patients.  The use of verapamil and diltiazem is specifically contraindicated under these circumstances.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7756, 0, 'Isradipine', 'Coronary Artery Disease', 'Increased frequency, duration, and/or severity of angina, as well as acute myocardial infarction, have rarely developed during initiation or dosage increase of calcium channel blockers (CCBs), particularly in patients with severe obstructive coronary artery disease and those treated with immediate-release formulations.  The mechanism of this effect is not established.  Therapy with CCBs should be administered cautiously in patients with significant coronary artery disease.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7757, 0, 'Isradipine', 'Liver Diseases', 'Calcium channel blockers (CCBs) are extensively metabolized by the liver.  The half-lives of CCBs may be prolonged substantially in patients with severe hepatic impairment, with the potential for significant drug accumulation.  In addition, the use of some CCBs has been associated with elevations in serum transaminases, both with and without concomitant elevations in alkaline phosphatase and bilirubin.  While these effects may be transient and reversible, some patients have developed cholestasis or hepatocellular injury.  Therapy with CCBs should be administered cautiously and often at reduced dosages in patients with significantly impaired hepatic function.  Periodic monitoring of liver function is advised.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7758, 0, 'Isradipine', 'Heart Failure', 'Calcium channel blockers (CCBs) may have varying degrees of negative inotropic effect.  Congestive heart failure (CHF), worsening of CHF, and pulmonary edema have occurred in some patients treated with a CCB, primarily verapamil.  Some CCBs have also caused mild to moderate peripheral edema due to localized vasodilation of dependent arterioles and small blood vessels, which can be confused with the effects of increasing left ventricular dysfunction.  Although some CCBs have been used in the treatment of CHF, therapy with CCBs should be administered cautiously in patients with severe left ventricular dysfunction (e.g., ejection fraction < 30%) or moderate to severe symptoms of cardiac failure and in patients with any degree of ventricular dysfunction if they are receiving a beta-adrenergic blocker.  Likewise, caution is advised in patients with acute myocardial infarction and pulmonary congestion documented by X-ray on admission, since associated heart failure may be acutely worsened by administration of a CCB.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7759, 0, 'Isradipine', 'Intestinal Obstruction', 'The controlled-release formulation of isradipine (Dynacirc CR) contains a non-deformable material.  There have been rare reports of obstructive symptoms in patients with known strictures following the ingestion of similar sustained-release products.  Therapy with the controlled-release formulation of isradipine should be administered cautiously in patients with preexisting severe gastrointestinal narrowing or obstruction, whether pathologic or iatrogenic.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7760, 0, 'Ivabradine', 'Cardiac Conduction System Disease', 'The use of ivabradine is contraindicated in sick sinus syndrome, sinoatrial block, or 3rd degree AV block, unless a functioning demand pacemaker is present, in those patients that are pacemaker dependent (heart rate maintained exclusively by the pacemaker), and in patients with resting heart rate less than 60 bpm prior to treatment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7761, 0, 'Ivabradine', 'Heart Failure', 'The use of ivabradine is contraindicated in acute decompensated heart failure.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7762, 0, 'Ivabradine', 'Hepatic Insufficiency', 'Ivabradine is contraindicated in patients with severe hepatic impairment as it has not been studied in this population and an increase in systemic exposure is anticipated.  No dose adjustment is required in patients with mild or moderate hepatic impairment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7763, 0, 'Ivabradine', 'Hypotension', 'The use of ivabradine is contraindicated in those patients with blood pressure less than 90/50 mmHg.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7764, 0, 'Ivabradine', 'Kidney Diseases', 'No dosage adjustment is required for patients with creatinine clearance 15 to 60 mL/min.  Care should be exercised when using this agent in patients with creatinine clearance below 15 mL/min as no data are available.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7765, 0, 'Ivacaftor', 'Cataract', 'Cases of non- congenital lens opacities or cataracts have been reported in pediatric patients treated with ivacaftor, and although other risk factors could be present in some cases, a possible risk attributable to this medication cannot be excluded.  Baseline and ophthalmological examinations are recommended in pediatric patients initiating treatment.  Caution is advised in patients with ophthalmologic conditions.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7766, 0, 'Ivacaftor', 'Hepatic Insufficiency', 'Elevated transaminases have been reported in patients with cystic fibrosis receiving ivacaftor.  It is recommended that liver function tests are assessed prior to treatment, every 3 months during the first year, and annually thereafter.  Patients with increased levels should be closely monitored until the abnormalities resolve, and dosing should be interrupted in patients with ALT or AST of greater than 5 times the upper limit of normal (ULN).  In patients with hepatic impairment, no dose adjustment is necessary in patients with mild impairment, but a reduced dose of ivacaftor is recommended in patients with moderate impairment (see prescribing information for dosing recommendations).  Studies have not been conducted in patients with severe hepatic impairment, but exposure is expected to be higher than in patients with moderate impairment.  Therefore, caution should be used on these patients, and a reduced dose is recommended after weighing the risks and benefits of treatment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7767, 0, 'Ivacaftor', 'Kidney Diseases', 'Ivacaftor has not been studied in patients with renal impairment.  No dose adjustment is necessary for patients with mild or moderate renal impairment, however, caution is recommended in patients with severe renal impairment or end-stage renal disease.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7768, 0, 'Itraconazole', 'Heart Failure', 'Itraconazole may possess a dose-related negative inotropic effect.  Transient, asymptomatic decreases in left ventricular ejection fraction were observed with IV administration in healthy volunteers; these resolved before the next infusion.  Additionally, cases of congestive heart failure (CHF), peripheral edema, and pulmonary edema have been reported during postmarketing experience in patients treated for onychomycosis and/or systemic fungal infections.  Itraconazole should not be used to treat onychomycosis in patients with evidence of ventricular dysfunction such as CHF or history of CHF; itraconazole should not be used for other indications in such patients unless the benefit clearly outweighs the risk.  The risks and benefits of itraconazole therapy should be reviewed carefully in patients with risk factors for CHF (including cardiac disease [e.g., ischemic and valvular disease], significant pulmonary disease [e.g., chronic obstructive pulmonary disease], renal failure and other edematous disorders).  Patients with risk factors for CHF should be advised of the signs/symptoms of CHF, treated with caution, and monitored for signs/symptoms of CHF during therapy.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7769, 0, 'Itraconazole', 'Liver Diseases', 'Limited data are available on the use of oral itraconazole in patients with liver dysfunction.  Itraconazole has been associated with rare cases of serious hepatotoxicity (including liver failure and death).  Caution is recommended when this drug is used in patients with liver dysfunction; such patients should be carefully monitored during therapy.  Treatment with itraconazole is strongly discouraged in patients with elevated or abnormal liver enzymes, with active liver disease, or who had liver toxicity with other drugs unless the situation is serious or life-threatening and the expected benefit exceeds the risk.  Liver function monitoring is recommended for patients with preexisting hepatic function abnormalities or those who had liver toxicity with other drugs.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7770, 0, 'Itraconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7771, 0, 'Itraconazole', 'Achlorhydria', 'Itraconazole 100-mg capsules should be administered after a full meal.  Under fasted conditions, absorption of itraconazole from the 100-mg capsule formulation was diminished with decreased gastric acidity.  Studies conducted under fasted conditions showed that taking the 100-mg capsule formulation with 8 ounces of a non-diet cola beverage enhanced absorption of itraconazole in AIDS patients with relative or absolute achlorhydria; this increase relative to the effects of a full meal is unknown.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7772, 0, 'Itraconazole', 'Cystic Fibrosis', 'In a study using itraconazole oral solution in cystic fibrosis patients, therapeutic drug levels varied and were not reached in some patients.  Alternative therapy should be considered for patients who do not respond to itraconazole oral solution or itraconazole 100-mg capsules.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7773, 0, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7774, 0, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7775, 0, 'Isoxsuprine', 'Hemorrhage', 'The use of isoxsuprine is contraindicated in patients with arterial bleeding.  The alpha adrenoreceptor antagonism of isoxsuprine produces vasodilation that may exacerbate arterial bleeding.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7776, 0, 'Istradefylline', 'Liver Failure', 'Istradefylline has not been studied in patients with severe hepatic impairment (Child-Pugh Class C), and its use should be avoided in these patients.  In patients with moderate hepatic impairment (Child-Pugh B), the steady-state exposures were predicted to be 3.3-fold higher.  Therefore, the maximum recommended dosage of istradefylline in patients with moderate hepatic impairment (Child-Pugh B) is 20 mg once daily.  Patients should be closely monitored for adverse events when receiving treatment.  No dose adjustment is needed in patients with mild hepatic impairment.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7777, 0, 'Istradefylline', 'Kidney Failure, Chronic', 'Istradefylline has not been evaluated in patients with end-stage renal disease (ESRD) (CrCl <15 mL/min) or ESRD requiring hemodialysis.  Caution is advised if prescribed in these patients.  No dosage adjustment is needed in patients with mild, moderate or severe renal impairment.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7778, 0, 'Istradefylline', 'Psychotic Disorders', 'Because of the potential risk of exacerbating psychosis, patients with a major psychotic disorder should not be treated with istradefylline.  Consider dosage reduction or discontinuation if a patient develops hallucinations or psychotic behaviors while taking this drug.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7779, 0, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7780, 0, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7781, 0, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7782, 0, 'Isosorbide dinitrate', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7783, 0, 'Isosorbide dinitrate', 'Intracranial Hypertension', 'Organic nitrates and nitrites can increase cerebrospinal fluid pressure.  Therapy with these agents should be administered cautiously, if at all, in patients with or at risk for intracranial hypertension, including those with cerebral hemorrhage, intracranial lesions, or recent head trauma.', '3', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7784, 0, 'Isosorbide dinitrate', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', 'DDInter');
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, source) VALUES (7785, 0, 'Isosorbide dinitrate', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', 'DDInter');
